Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT UBC Medical Indonesia TbkISX:LABS Debt-to-EBITDA is 0.00 as of . 20. The stock has 2 warning signs investors should review. Among 475 Medical Devices & Instruments companies, PT UBC Medical Indonesia Tbk ranks worse than 210526.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PT UBC Medical Indonesia Tbk's Debt-to-EBITDA or its related term are showing as below:
ISX:LABS's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.63 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PT UBC Medical Indonesia Tbk Debt-to-EBITDA Related Terms
PT UBC Medical Indonesia Tbk Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT UBC Medical Indonesia Tbk Debt-to-EBITDA Chart
PT UBC Medical Indonesia Tbk Annual Data
Trend
Debt-to-EBITDA
PT UBC Medical Indonesia Tbk Semi-Annual Data
Debt-to-EBITDA
ISX:LABS vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, PT UBC Medical Indonesia Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT UBC Medical Indonesia Tbk Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PT UBC Medical Indonesia Tbk's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT UBC Medical Indonesia Tbk's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (. 20) EBITDA data.
PT UBC Medical Indonesia Tbk (ISX:LABS) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT UBC Medical Indonesia Tbk. According to the industry distribution chart, PT UBC Medical Indonesia Tbk ranks #999999 out of 475 companies in the Medical Devices & Instruments industry.
Is PT UBC Medical Indonesia Tbk's Debt-to-EBITDA too high?
PT UBC Medical Indonesia Tbk's current Debt-to-EBITDA is 0.00. Based on the distribution chart, PT UBC Medical Indonesia Tbk ranks #999999 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does PT UBC Medical Indonesia Tbk's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, PT UBC Medical Indonesia Tbk ranks #999999 out of 475 companies for Debt-to-EBITDA. This places PT UBC Medical Indonesia Tbk in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT UBC Medical Indonesia Tbk. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT UBC Medical Indonesia Tbk's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT UBC Medical Indonesia Tbk stock overvalued right now?
PT UBC Medical Indonesia Tbk (ISX:LABS) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PT UBC Medical Indonesia Tbk (ISX:LABS), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT UBC Medical Indonesia Tbk is a distribution company. It engages in wholesale of Laboratory Equipment, Pharmaceutical Equipment, and Medical Equipment for Humans and animals, which includes the wholesale of laboratory equipment, pharmaceutical equipment, and medical equipment. It divides its main marketed medical equipment products into two categories Instruments, in the form of equipment, machines, and analyzers, are used in laboratories. The function of instruments is to process specimens or biological samples to measure and examine the levels of certain substances/contents; and Consumables include single-use medical devices used for treatment or health examinations and Reagents include chemical reagents used in laboratory tests to detect, measure, examine, & produce other substances.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:LABS has been successfully added to your 
